


HIV PrEP with Tenofovir DF for Persons who Inject Drugs
Bangkok Tenofovir Study

HIV PrEP with Tenofovir DF for Persons who Inject Drugs


Bangkok Tenofovir Study: Background

- **Background:** Randomized, phase 3, double-blind, placebo-controlled trial conducted in Bangkok, Thailand that examined efficacy and safety of tenofovir DF as preexposure prophylaxis in persons who inject drugs
- **Inclusion Criteria** (2,413 enrolled [1,924 men; 489 women])
 - HIV-1-seronegative adults 20-60 years of age
 - Reported injecting drugs in prior year
 - All participants received risk-reduction counseling
 - All participants received bleach and condoms
 - Excluded if hepatitis B surface antigen positive (HBsAg+)
 - Excluded if pregnant or breastfeeding
- **Treatment Arms**
 - Placebo: 1 pill daily
 - Tenofovir DF: 1 pill daily



HIV PrEP with Tenofovir DF for Persons who Inject Drugs Bangkok Tenofovir Study: Results

Number of Infections: Modified Intent-to-Treat Analysis




Analysis does not include 2 additional HIV infections in placebo group identified at enrollment; Follow-up time: mean 4.0 years (SD 2.1; max 6.9 years)

HIV PrEP with Tenofovir DF for Persons who Inject Drugs

Bangkok Tenofovir Study: Results

Risk Reduction Compared with Placebo: Modified Intent-to-Treat Analysis



Analysis does not include 2 additional HIV infections in placebo group identified at enrollment; Follow-up time: mean 4.0 years (SD 2.1; max 6.9 years)

HIV Preexposure Prophylaxis in Injection Drug Users Bangkok Tenofovir Trial: Conclusions

Interpretation: “In this study, daily oral tenofovir reduced the risk of HIV infection in people who inject drugs. Pre-exposure prophylaxis with tenofovir can now be considered for use as part of an HIV prevention package for people who inject drugs.”

Acknowledgments

The **National HIV Curriculum** is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling \$1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

